Prurigo Nodularis Clinical Trial
Official title:
A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study. The study consists of 3 periods: - Screening period: 2 to 4 weeks. - Treatment period: 24 weeks. - Post-intervention follow-up period: 16 weeks. The study duration will be approximately 42 to 44 weeks for each participant (including screening, treatment, and follow-up periods). The total number of planned study visits for each participant will be 6.
Status | Recruiting |
Enrollment | 18 |
Est. completion date | November 3, 2027 |
Est. primary completion date | October 28, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Months to 17 Years |
Eligibility | Inclusion Criteria: - Participants must be =6 months to <18 years of age, at the time of signing the informed consent. - A clinical diagnosis of prurigo nodularis (PN) at least 3 months prior to screening, an Investigator's global assessment for prurigo nodularis stage (IGA PN-S) score of =2 with presence of =6 pruriginous lesions at Baseline. The lesions should be present on =2 different body surface areas at Baseline. - On the worst itch numerical rating scale (WI-NRS) (for participants aged =6 years to <18 years old at the screening visit) or worst-scratch/itch NRS (for participants aged =6 months to <6 years at the screening visit) ranging from 0 to 10, participants must have an average worst itch score of =7 in the 7 days prior to Day 1. NOTE: Baseline pruritus NRS average score for maximum itch intensity will be determined based on the average of daily NRS scores for maximum intensity (the daily score ranges from 0 to 10) during the 7 days immediately preceding the Day 1/Baseline visit. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score. - Participants/Caregivers must be willing and able to complete a daily symptom e-Diary for the duration of the study. - Contraceptive use by male and female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: - Presence of active moderate to severe lesions of atopic dermatitis (AD), and/or other skin conditions that may interfere with the PN diagnosis including but not limited to the following: scabies, psoriasis, lymphomatoid papulosis, habitual picking, dermatitis herpetiformis, sporotrichosis, and bullous disease. - Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, or antifungals within 2 weeks before the screening visit or during the screening period. NOTE: Participants may be rescreened after infection resolves. - Known or suspected immunodeficiency, including history of invasive opportunistic infections (eg, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, and aspergillosis) despite infection resolution, or otherwise recurrent infections of abnormal frequency or prolonged duration suggesting an immune compromised status, as judged by the Investigator. - Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the participant's participation in the study. - Planned or anticipated major surgical procedure during the participant's participation in this clinical trial. - Participants who has taken biologic therapy/systemic immunosuppressant/ immunomodulator within 4 weeks before the screening visit or 5 half-lives, whichever is longer. - Current participation to any clinical trial of an investigational drug or device or participation within 3 months before the screening visit or 5 half-lives of the investigational compound, whichever is longer. - Participation in prior dupilumab clinical study or have been treated with commercially available dupilumab. |
Country | Name | City | State |
---|---|---|---|
United States | Pediatric Center Of Excellence Site Number : 8400005 | Coral Gables | Florida |
United States | Mission Dermatology Center Site Number : 8400011 | Rancho Santa Margarita | California |
United States | Vital Prospects Clinical Research Institute, P.C. Site Number : 8400002 | Tulsa | Oklahoma |
Lead Sponsor | Collaborator |
---|---|
Sanofi | Regeneron Pharmaceuticals |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Concentration of dupilumab in serum | Concentration of dupilumab in serum over time | Day 1 to Week 40 | |
Secondary | Incidence of treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs) | Date of signed ICF (2-4 weeks before Day 1) to Week 40 | ||
Secondary | Incidence of anti-drug antibodies (ADA) to dupilumab over time | Day 1 to Week 40 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05038982 -
Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin
|
Phase 2 | |
Completed |
NCT00869089 -
Safety and Efficacy of CC-10004 for Prurigo Nodularis
|
Phase 2 | |
Completed |
NCT04501666 -
An Efficacy and Safety Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis
|
Phase 3 | |
Completed |
NCT03181503 -
Safety and Efficacy of Nemolizumab in PN
|
Phase 2 | |
Completed |
NCT03630198 -
Pain Outcomes Following Intralesional Corticosteroid Injections
|
Phase 4 | |
Completed |
NCT04944862 -
A Study of CDX-0159 in Patients With Prurigo Nodularis
|
Phase 1 | |
Completed |
NCT05061693 -
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
|
Phase 2 | |
Completed |
NCT03546816 -
Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
|
Phase 3 | |
Not yet recruiting |
NCT06201715 -
Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis
|
N/A | |
Completed |
NCT02174419 -
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
|
Phase 2/Phase 3 | |
Terminated |
NCT03540160 -
Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)
|
Phase 3 | |
Recruiting |
NCT06427122 -
Effect of EMD Protocol for Urge on Dermatology-specific Quality of Life
|
N/A | |
Completed |
NCT03816891 -
Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis
|
Phase 2 | |
Recruiting |
NCT05764161 -
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
|
Phase 3 | |
Completed |
NCT02196324 -
A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)
|
Phase 2 | |
Not yet recruiting |
NCT06424470 -
Study on the Treatment of Prurigo Nodularis With Stapokibart Injection
|
Phase 3 | |
Recruiting |
NCT03576287 -
Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis
|
Phase 1/Phase 2 | |
Completed |
NCT05052983 -
A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis
|
Phase 3 | |
Active, not recruiting |
NCT04204616 -
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
|
Phase 3 | |
Recruiting |
NCT06213831 -
A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream
|
Phase 1 |